Table 2.
Clinical response | R (n = 5) | PR (n = 5) | NR (n = 8) |
Females | 0 (0%) | 2 (40%) | 3 (37%) |
Age (years)* | 24 ± 10.1 | 40 ± 19.8 | 37 ± 9.7 |
Disease duration (years)* | 2 ± 1.5 | 7 ± 23.3 | 1 ± 10.6 |
HLA-B27 positive | 4 (80%) | 4 (80%) | 7 (87%) |
Localisation | |||
Axial | 3 (17%) | 4 (17%) | 5 (17%) |
Axial and peripheral | 15 (83%) | 16 (83%) | 17 (83%) |
CRP (mg/L) at M0* | 12 ± 15.5 | 8 ± 4.8 | 2 ± 3.2 |
ASDAS at M0* | 4.0 ± 0.6 | 2.4 ± 0.4 | 2.2 ± 0.8 |
BASDAI at M0* | 1.0 ± 0.4 | 1.8 ± 0.6 | 5.0 ± 2.2 |
Δ ASDAS* | 2.8 ± 0.5 | 1.3 ± 0.3 | 0.1 ± 0.7 |
*Medians ± SD.